Press Release

FDA agrees with Phase 2b/3 clinical design, including primary endpoint and development approach, providing clear regulatory pathway to conduct two studies under single protocol Dempsey brings proven track record of ophthalmology commercialization and will present company update at Eyecelerator ahead of American Academy of Ophthalmology Annual Meeting 2025   REDWOOD CITY, Calif., October 14, 2025 … Read more

Migaldendranib (MGB), a subcutaneous nanomedicine, represents potential paradigm shift from frequent intravitreal injections   REDWOOD CITY, Calif., October 8, 2025 — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood-retinal barrier in regions of inflammation selectively targeting and reprogramming activated cells in the retina, today announced an upcoming presentation at … Read more

Migaldendranib (MGB) is a new class of targeted nanomedicine for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with a novel mechanism of action that normalizes VEGF expression. End of study, 40-week results demonstrated that MGB, delivered via subcutaneous (subQ) administration, is safe and well-tolerated with no MGB treatment-related ocular … Read more

 Company to present topline 40-week Phase 2 study efficacy and safety results of migaldendranib (MGB), a novel first-in-class nanomedicine for DME and nAMD  Subcutaneous at-home administration represents a potential paradigm shift from frequent in-office intravitreal injections  Chief Medical Officer also to present at the Ophthalmology Futures Forums: Retina Forum 2025 REDWOOD CITY, Calif., August 26, … Read more

Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with DME and wet-AMD  Novel subcutaneous delivery may offer a more patient-friendly alternative to intravitreal injections, with the potential to significantly reduce treatment burden  REDWOOD CITY, Calif., June 30, 2025 — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class … Read more

Novel nanomedicine radiotracer crosses blood brain barrier in patients with neuroinflammation  Tumor macrophage radiotracer achieves 41.6% peak tumor uptake in preclinical studies  REDWOOD CITY, Calif., June 23, 2025 — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions … Read more

Company to showcase breakthrough imaging agents advancing precision medicine in neurology and oncology   REDWOOD CITY, Calif., June 17, 2025 — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced it will present data … Read more

Ashvattha will present Phase 2 data on migaldendranib, a subcutaneous therapy for DME and wet AMD, which could offer a more patient-friendly alternative to current injection-based treatments  Company is exploring new technology to normalize VEGF expression, potentially enhancing both safety and efficacy of treatments for retinal and other diseases   REDWOOD CITY, Calif., June 10, … Read more

Subcutaneous administration generally safe and well-tolerated across multiple doses >80% reduction in anti-VEGF intravitreal injection burden in wet AMD and DME study eyes and >75% total reduction in fellow eyes Maintenance of vision and anatomical improvements in study eye and fellow eye of patients previously treated First-in-class dendrimer nanomedicine that treats both eyes simultaneously with … Read more

Presentations to highlight updated Phase 2 subcutaneous migaldendranib (MGB) data for wet AMD and DME REDWOOD CITY, Calif., April 15, 2025 — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced it will present … Read more